PureWick®碧舒芯TM是碧迪医疗全球首创的女性卧床排尿管理创新解决方案，其中包括专门为女性卧 床排尿而设计的非侵入式导尿产品。该产品能够借助负压装置，更加舒适地收集患者排出的尿液，并导 入集液桶中，为临床女性患者及护理人员提供简单、非侵入式排尿管理方案，从而在很大程度上改善卧 床女性的护理体验和生活质量，简化了护理人员的工作流程、提高了效率，也让女性患者的舒适度与尊 严得到了更好的保障。 即日起，北京地区用户在京东App上的"秒送"页面搜索"purewick"即可下单，同时将获得京东护士到家 提供的产品操作、护理指导等服务。该服务的提供者均为来自京东护士到家服务团队的执业护士，他们 具有丰富的临床护理经验，且大部分拥有三级及以上医院的临床护理从业经历。在保证专业护理服务质 量的同时，也能最大程度地保护女性患者隐私。 本报讯 （记者袁传玺）近日，京东健康股份有限公司（以下简称"京东健康"）与全球领先的医疗技术 公司碧迪医疗共同推出"关爱卧床女性健康·专业护理暖心到家"服务。该服务以北京为试点，用户通过 京东买药秒送购买PureWick®碧舒芯TM相关产品，可同时获得京东护士到家提供的产品操作、护理指 导等 ...

Summary of Becton, Dickinson and Company (BDX) 2025 Conference Call Company Overview - **Company**: Becton, Dickinson and Company (BDX) - **Conference Date**: May 13, 2025 - **CEO**: Tom Poland Key Points Company Performance and Strategy - Over the past five years, BDX has transformed into a nearly $22 billion company, focusing on innovation and quality improvements [4][5] - The company has achieved a compound annual growth rate (CAGR) of approximately 5.6% in revenue since launching BD 2025 [5] - Current revenue growth is impacted by macroeconomic factors, including China's Value-Based Pricing (VBP) and life sciences funding constraints [5][6] Revenue Growth Challenges - Revenue growth has slowed, with a projected decline in China of high single digits to low double digits for the year [6][16] - Life sciences revenue growth was flat last year and is expected to decline in the low single digits this year due to research funding constraints [6][7] - The farm systems business, which previously saw 12% growth, is recovering after a flat performance last year [7][20] Q2 Performance and Guidance - Q2 growth was only 0.9%, significantly lower than the initial expectation of 2.75% [11][12] - Key factors for the decline included reduced NIH funding impacting instrument spending and increased VBP in China [12][13] - Full-year guidance was lowered by $200 million, reflecting the challenges in China, biosciences spending, and the ramp-up of Bactech [16][17] Actions Taken Post-Q2 - BDX has implemented several actions to address the challenges, including enhancing commercial excellence and increasing R&D investments [18][19] - The company is focusing on key growth catalysts such as PureWick and its peripheral vascular business [19][20] Margin and Cost Management - BDX has seen a gross margin expansion of 190 basis points, attributed to the BD Excellence initiative aimed at driving efficiency [24][25] - The company plans to continue investing in R&D and selling, with a focus on maintaining strong operating margins [24][26] Tariffs and Supply Chain Adjustments - The company is actively managing tariff impacts, with a focus on sourcing changes to mitigate costs [27][29] - Approximately 80% of U.S. revenue is derived from products manufactured domestically or tariff-exempt [32] Life Sciences Separation Update - The separation of the life sciences business is on track, with an announcement expected in summer 2025 [40][43] - The bioscience business is recognized for its innovative assets, including advancements in cancer research technology [41][42] Future Outlook - The RemainCo business is projected to maintain mid-single-digit growth, supported by strong market positions and recurring revenue from consumables [46][48] - BDX is focused on disciplined capital deployment, avoiding large transformational M&A, and prioritizing high-return investments [51][53] Conclusion - BDX is navigating a challenging macro environment while focusing on innovation, operational excellence, and strategic growth initiatives to enhance shareholder value [4][5][19]

Becton, Dickinson and Company (BDX) Q2 2025 Earnings Call May 01, 2025 08:00 AM ET Company Participants Greg Rodetis - SVP, Treasurer & Head of Investor RelationsTom Polen - Chairman, CEO & PresidentChristopher DelOrefice - Executive VP & CFOMatthew Taylor - Managing DirectorTravis Steed - Managing Director - Equity ResearchMichael Feld - President & EVPDavid Roman - Managing Director Conference Call Participants Larry Biegelsen - AnalystRobbie Marcus - AnalystPatrick Wood - AnalystMatthew Miksic - Analyst ...